Do analysts prefer QCLS or OKYO?

OKYO Pharma has a consensus target price of $6.33, suggesting a potential upside of 301.10%. Given OKYO Pharma's stronger consensus rating and higher probable upside, analysts clearly believe OKYO Pharma is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 OKYO Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger valuation and earnings, QCLS or OKYO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A OKYO Pharma N/A N/A -$4.71M N/A N/A

Is QCLS or OKYO more profitable?

OKYO Pharma's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mymd Pharmaceuticals N/A -76.40% -35.10% OKYO Pharma N/A N/A N/A

Do analysts recommend QCLS or MCRB?

Seres Therapeutics has a consensus target price of $17.00, indicating a potential upside of 144.32%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Seres Therapeutics is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is QCLS or MCRB more profitable?

Mymd Pharmaceuticals' return on equity of -76.40% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mymd Pharmaceuticals N/A -76.40% -35.10% Seres Therapeutics N/A -130.29% -35.35%

Do analysts prefer QCLS or CTOR?

Citius Oncology has a consensus target price of $6.00, indicating a potential upside of 769.57%. Given Citius Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Citius Oncology is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has preferable valuation and earnings, QCLS or CTOR?

Citius Oncology is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A Citius Oncology N/A N/A -$24.76M -$0.47 N/A

Is QCLS or CTOR more profitable?

Mymd Pharmaceuticals' return on equity of -76.40% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Mymd Pharmaceuticals N/A -76.40% -35.10% Citius Oncology N/A -99.47% -42.16%

Do analysts rate EDSA or QCLS?

Edesa Biotech presently has a consensus target price of $5.00, indicating a potential downside of 36.99%. Given Edesa Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Edesa Biotech is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, EDSA or QCLS?

Edesa Biotech is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edesa Biotech N/A N/A -$7.19M -$1.34 N/A Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A

Is EDSA or QCLS more profitable?

Mymd Pharmaceuticals' return on equity of -76.40% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -286.52% -75.36% Mymd Pharmaceuticals N/A -76.40% -35.10%

Do analysts rate QCLS or INKT?

MiNK Therapeutics has a consensus target price of $35.00, indicating a potential upside of 184.55%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Mymd Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MiNK Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40

Which has better earnings and valuation, QCLS or INKT?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A

Is QCLS or INKT more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mymd Pharmaceuticals N/A -76.40% -35.10% MiNK Therapeutics N/A N/A -118.57%

Mymd Pharmaceuticals (QCLS) Competitors

$4.03 +0.22 (+5.70%)

As of 09:35 AM Eastern

Compare

QCLS vs. OKYO, MCRB, CTOR, EDSA, and INKT

Should you buy Mymd Pharmaceuticals stock or one of its competitors? MarketBeat compares Mymd Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mymd Pharmaceuticals include OKYO Pharma (OKYO), Seres Therapeutics (MCRB), Citius Oncology (CTOR), Edesa Biotech (EDSA), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry.

How does Mymd Pharmaceuticals compare to OKYO Pharma?

Mymd Pharmaceuticals (NASDAQ:QCLS) and OKYO Pharma (NASDAQ:OKYO) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

OKYO Pharma's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
OKYO Pharma	N/A	N/A	N/A

In the previous week, OKYO Pharma had 2 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 2 mentions for OKYO Pharma and 0 mentions for Mymd Pharmaceuticals. OKYO Pharma's average media sentiment score of 0.49 beat Mymd Pharmaceuticals' score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Mymd Pharmaceuticals	Neutral
OKYO Pharma	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A

9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 0.9% of Mymd Pharmaceuticals shares are owned by company insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mymd Pharmaceuticals has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market.

OKYO Pharma has a consensus target price of $6.33, suggesting a potential upside of 301.10%. Given OKYO Pharma's stronger consensus rating and higher probable upside, analysts clearly believe OKYO Pharma is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

OKYO Pharma beats Mymd Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Seres Therapeutics?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

Seres Therapeutics has a consensus target price of $17.00, indicating a potential upside of 144.32%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Seres Therapeutics is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Seres Therapeutics had 9 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 9 mentions for Seres Therapeutics and 0 mentions for Mymd Pharmaceuticals. Seres Therapeutics' average media sentiment score of 1.13 beat Mymd Pharmaceuticals' score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Mymd Pharmaceuticals	Neutral
Seres Therapeutics	Positive

Seres Therapeutics has higher revenue and earnings than Mymd Pharmaceuticals. Seres Therapeutics is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A
Seres Therapeutics	$790K	85.26	$5.70M	-$5.17	N/A

Mymd Pharmaceuticals' return on equity of -76.40% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
Seres Therapeutics	N/A	-130.29%	-35.35%

Mymd Pharmaceuticals has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.13, meaning that its stock price is 87% less volatile than the broader market.

9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 0.9% of Mymd Pharmaceuticals shares are owned by insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Seres Therapeutics beats Mymd Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Citius Oncology?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Citius Oncology (NASDAQ:CTOR) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

In the previous week, Mymd Pharmaceuticals' average media sentiment score of 0.00 equaled Citius Oncology'saverage media sentiment score.

Company	Overall Sentiment
Mymd Pharmaceuticals	Neutral
Citius Oncology	Neutral

Mymd Pharmaceuticals has a beta of 2.17, suggesting that its share price is 117% more volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.41, suggesting that its share price is 241% more volatile than the broader market.

Mymd Pharmaceuticals' return on equity of -76.40% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
Citius Oncology	N/A	-99.47%	-42.16%

9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 0.9% of Mymd Pharmaceuticals shares are owned by insiders. Comparatively, 9.8% of Citius Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Citius Oncology has a consensus target price of $6.00, indicating a potential upside of 769.57%. Given Citius Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Citius Oncology is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Citius Oncology is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

Summary

Citius Oncology beats Mymd Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to Edesa Biotech?

Edesa Biotech (NASDAQ:EDSA) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by company insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Edesa Biotech's average media sentiment score of 0.00 equaled Mymd Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Edesa Biotech	Neutral
Mymd Pharmaceuticals	Neutral

Edesa Biotech is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

Edesa Biotech has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market.

Edesa Biotech presently has a consensus target price of $5.00, indicating a potential downside of 36.99%. Given Edesa Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Edesa Biotech is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mymd Pharmaceuticals' return on equity of -76.40% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-286.52%	-75.36%
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

Summary

Edesa Biotech beats Mymd Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Mymd Pharmaceuticals compare to MiNK Therapeutics?

Mymd Pharmaceuticals (NASDAQ:QCLS) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

MiNK Therapeutics has a consensus target price of $35.00, indicating a potential upside of 184.55%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Mymd Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

In the previous week, MiNK Therapeutics had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 1 mentions for MiNK Therapeutics and 0 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 0.00 equaled MiNK Therapeutics'average media sentiment score.

Company	Overall Sentiment
Mymd Pharmaceuticals	Neutral
MiNK Therapeutics	Neutral

9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 0.9% of Mymd Pharmaceuticals shares are owned by insiders. Comparatively, 20.4% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Mymd Pharmaceuticals has a beta of 2.17, suggesting that its share price is 117% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A

MiNK Therapeutics' return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
MiNK Therapeutics	N/A	N/A	-118.57%

Summary

MiNK Therapeutics beats Mymd Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Mymd Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QCLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QCLS vs. The Competition

Export

Metric	Mymd Pharmaceuticals	In Vitro, In Vivo Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$16.51M	$616.64M	$5.00B	$12.32B
Dividend Yield	N/A	N/A	11.45%	5.88%
P/E Ratio	-0.19	N/A	22.00	23.95
Price / Sales	N/A	148.29	155.05	107.90
Price / Cash	N/A	352.76	39.06	53.76
Price / Book	0.78	36.68	15.93	6.41
Net Income	-$11.63M	-$18.48M	$115.37M	$337.14M
7 Day Performance	0.17%	-0.89%	-1.70%	-1.07%
1 Month Performance	-3.66%	-9.24%	-2.47%	0.48%
1 Year Performance	N/A	-37.14%	11.40%	28.42%

Mymd Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QCLS Mymd Pharmaceuticals	1.0629 of 5 stars	$4.03 +5.7%	N/A	N/A	$16.51M	N/A	N/A	6	Positive News
OKYO OKYO Pharma	2.8051 of 5 stars	$1.59 +1.3%	$6.33 +298.3%	-32.6%	$63.67M	N/A	N/A	7	News Coverage
MCRB Seres Therapeutics	2.9283 of 5 stars	$6.61 +2.3%	$22.00 +232.8%	-18.9%	$62.56M	$790K	N/A	330	Positive News Analyst Forecast Analyst Revision
CTOR Citius Oncology	1.4644 of 5 stars	$0.67 +1.4%	$6.00 +795.9%	-74.2%	$61.39M	N/A	N/A	N/A
EDSA Edesa Biotech	0.5958 of 5 stars	$7.35 +6.8%	$5.00 -32.0%	+297.5%	$61.18M	N/A	N/A	20	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QCLS) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. OKYO, MCRB, CTOR, EDSA, and INKT

How does Mymd Pharmaceuticals compare to OKYO Pharma?

Summary

How does Mymd Pharmaceuticals compare to Seres Therapeutics?

Summary

How does Mymd Pharmaceuticals compare to Citius Oncology?

Summary

How does Mymd Pharmaceuticals compare to Edesa Biotech?

Summary

How does Mymd Pharmaceuticals compare to MiNK Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mymd Pharmaceuticals (QCLS) Competitors

QCLS vs. OKYO, MCRB, CTOR, EDSA, and INKT

How does Mymd Pharmaceuticals compare to OKYO Pharma?

Is QCLS or OKYO more profitable?

Does the media prefer QCLS or OKYO?

Which has stronger valuation and earnings, QCLS or OKYO?

Do insiders & institutionals hold more shares of QCLS or OKYO?

Which has more risk & volatility, QCLS or OKYO?

Do analysts prefer QCLS or OKYO?

Summary

How does Mymd Pharmaceuticals compare to Seres Therapeutics?

Do analysts recommend QCLS or MCRB?

Does the media refer more to QCLS or MCRB?

Which has stronger earnings and valuation, QCLS or MCRB?

Is QCLS or MCRB more profitable?

Which has more risk & volatility, QCLS or MCRB?

Do insiders and institutionals believe in QCLS or MCRB?

Summary

How does Mymd Pharmaceuticals compare to Citius Oncology?

Does the media refer more to QCLS or CTOR?

Which has more volatility & risk, QCLS or CTOR?

Is QCLS or CTOR more profitable?

Do insiders & institutionals have more ownership in QCLS or CTOR?

Do analysts prefer QCLS or CTOR?

Which has preferable valuation and earnings, QCLS or CTOR?

Summary

How does Mymd Pharmaceuticals compare to Edesa Biotech?

Do insiders & institutionals believe in EDSA or QCLS?

Does the media prefer EDSA or QCLS?

Which has preferable valuation & earnings, EDSA or QCLS?

Which has more volatility and risk, EDSA or QCLS?

Do analysts rate EDSA or QCLS?

Is EDSA or QCLS more profitable?

Summary

How does Mymd Pharmaceuticals compare to MiNK Therapeutics?

Do analysts rate QCLS or INKT?

Does the media favor QCLS or INKT?

Do institutionals and insiders believe in QCLS or INKT?

Which has more volatility & risk, QCLS or INKT?

Which has better earnings and valuation, QCLS or INKT?

Is QCLS or INKT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QCLS vs. The Competition

Mymd Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools